{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:50:19Z","timestamp":1761126619938},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,10,24]],"date-time":"2010-10-24T00:00:00Z","timestamp":1287878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11046-010-9375-5","type":"journal-article","created":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T13:16:38Z","timestamp":1287839798000},"page":"261-266","source":"Crossref","is-referenced-by-count":14,"title":["Combination Efficacy of Voriconazole and Amphotericin B in the Experimental Disease in Immunodeficient Mice Caused by Fluconazole-resistant Cryptococcus neoformans"],"prefix":"10.1007","volume":"171","author":[{"given":"Eriques Gon\u00e7alves","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudete Rodrigues","family":"Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Latercia Tranches","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilene Rodrigues","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana da Silva","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valderez","family":"Gambale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato Araujo","family":"Prates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Sim\u00f5es","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,24]]},"reference":[{"key":"9375_CR1","doi-asserted-by":"crossref","DOI":"10.1128\/9781555818241","volume-title":"Cryptococcus neoformans","author":"A Casadevall","year":"1998","unstructured":"Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology; 1998."},{"key":"9375_CR2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/jmm.0.46206-0","volume":"55","author":"E Silva","year":"2006","unstructured":"Silva E, Baroni FA, Viani F, Ruiz LS, Gandra R, Auler M, Dias A, Gambale W, Paula C. Virulence profile of strains of cryptococcus neoformans var. grubii evaluated by experimental infection in balb\/c mice and correlation with exoenzyme activity. J Med Microbiol. 2006;55:139\u201342.","journal-title":"J Med Microbiol"},{"key":"9375_CR3","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/01.aids.0000287549.79368.33","volume":"21","author":"MC Pappalardo","year":"2007","unstructured":"Pappalardo MC, Paschoal RC, Melhem MS. Aids-associated central nervous system cryptococcosis: a brazilian case study. AIDS. 2007;21:1971\u20132.","journal-title":"AIDS"},{"key":"9375_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/02681219680000561","volume":"34","author":"KV Clemons","year":"1996","unstructured":"Clemons KV, Azzi R, Stevens DA. Experimental systemic cryptococcosis in scid mice. J Med Vet Mycol. 1996;34:331\u20135.","journal-title":"J Med Vet Mycol"},{"key":"9375_CR5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1128\/IAI.59.4.1423-1433.1991","volume":"59","author":"GB Huffnagle","year":"1991","unstructured":"Huffnagle GB, Yates JL, Lipscomb MF. T cell-mediated immunity in the lung: a cryptococcus neoformans pulmonary infection model using scid and athymic nude mice. Infect Immun. 1991;59:1423\u201333.","journal-title":"Infect Immun"},{"key":"9375_CR6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkg261","volume":"51","author":"JR Graybill","year":"2003","unstructured":"Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother. 2003;51:1373\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"9375_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11908-000-0015-y","volume":"2","author":"WG Powderly","year":"2000","unstructured":"Powderly WG. Cryptococcal meningitis in HIV-infected patients. Curr Infect Dis Rep. 2000;2:352\u20137.","journal-title":"Curr Infect Dis Rep"},{"key":"9375_CR8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkh361","volume":"54","author":"B Sar","year":"2004","unstructured":"Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in cryptococcus neoformans cambodian isolates: April 2000\u2013March 2002. J Antimicrob Chemother. 2004;54:563\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"9375_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/tcrm.2006.2.2.129","volume":"2","author":"J Peman","year":"2006","unstructured":"Peman J, Salavert M, Canton E, Jarque I, Roma E, Zaragoza R et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag. 2006;2:129\u201358.","journal-title":"Ther Clin Risk Manag"},{"key":"9375_CR10","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","volume":"50","author":"F Sabatelli","year":"2006","unstructured":"Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin b against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009\u201315.","journal-title":"Antimicrob Agents Chemother"},{"key":"9375_CR11","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1128\/AAC.00376-07","volume":"51","author":"LR Martinez","year":"2007","unstructured":"Martinez LR, Ntiamoah P, Gacser A, Casadevall A, Nosanchuk JD. Voriconazole inhibits melanization in cryptococcus neoformans. Antimicrob Agents Chemother. 2007;51:4396\u2013400.","journal-title":"Antimicrob Agents Chemother"},{"key":"9375_CR12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/AAC.48.6.2014-2020.2004","volume":"48","author":"D Duin van","year":"2004","unstructured":"van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on cryptococcus neoformans. Antimicrob Agents Chemother. 2004;48:2014\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"9375_CR13","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/421962","volume":"39","author":"JH Powers","year":"2004","unstructured":"Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis. 2004;39(Suppl 4):S228\u201335.","journal-title":"Clin Infect Dis"},{"key":"9375_CR14","unstructured":"Kurtzman CP, Fell JW. The yeasts: a taxonomic study. 4th ed. Amsterdam: Elsevier Science; 1998. 1055 p."},{"key":"9375_CR15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/JCM.16.1.22-29.1982","volume":"16","author":"R Ikeda","year":"1982","unstructured":"Ikeda R, Shinoda T, Fukazawa Y, Kaufman L. Antigenic characterization of cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol. 1982;16:22\u20139.","journal-title":"J Clin Microbiol"},{"key":"9375_CR16","volume-title":"Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A3. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.","edition":"3"},{"key":"9375_CR17","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.44.9.2435-2441.2000","volume":"44","author":"F Barchiesi","year":"2000","unstructured":"Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D et al. Interactions between triazoles and amphotericin B against cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44:2435\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"9375_CR18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkm123","volume":"60","author":"C Serena","year":"2007","unstructured":"Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother. 2007;60:162\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"9375_CR19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11046-006-0039-4","volume":"162","author":"N Mavrogiorgos","year":"2006","unstructured":"Mavrogiorgos N, Zaragoza O, Casadevall A, Nosanchuk JD. Efficacy of voriconazole in experimental cryptococcus neoformans infection. Mycopathologia. 2006;162:111\u20134.","journal-title":"Mycopathologia"},{"key":"9375_CR20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0891-5520(05)70398-6","volume":"11","author":"A Espinel-Ingroff","year":"1997","unstructured":"Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North Am. 1997;11:929\u201344.","journal-title":"Infect Dis Clin North Am"},{"key":"9375_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/AAC.50.1.113-120.2006","volume":"50","author":"P Schwarz","year":"2006","unstructured":"Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin b in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 2006;50:113\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"9375_CR22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"A Brouwer","year":"2004","unstructured":"Brouwer A, Rajanuwong A, Chierakul W, Griffin G, Larsen R, White N et al. Combination antifungal therapies for hiv-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764\u20137.","journal-title":"Lancet"},{"key":"9375_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1130-1406(07)70048-7","volume":"24","author":"FJ Pastor","year":"2007","unstructured":"Pastor FJ, Guarro J. The role of voriconazole in the treatment of emerging mycoses. Rev Iberoam Micol. 2007;24:228\u201332.","journal-title":"Rev Iberoam Micol"},{"key":"9375_CR24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01216-08","volume":"53","author":"GR Thompson 3rd","year":"2009","unstructured":"Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of cryptococcus gattii and cryptococcus neoformans. Antimicrob Agents Chemother. 2009;53:309\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"9375_CR25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/mmy.38.s1.305.315","volume":"38","author":"DA Stevens","year":"2000","unstructured":"Stevens DA, Kullberg BJ, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol. 2000;38(Suppl 1):305\u201315.","journal-title":"Med Mycol"},{"key":"9375_CR26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/AAC.49.2.512-517.2005","volume":"49","author":"PR Hsueh","year":"2005","unstructured":"Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM et al. Antifungal susceptibilities of clinical isolates of candida species, cryptococcus neoformans, and aspergillus species from taiwan: Surveillance of multicenter antimicrobial resistance in taiwan program data from 2003. Antimicrob Agents Chemother. 2005;49:512\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"9375_CR27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1097\/00002030-200111230-00026","volume":"15","author":"G Friese","year":"2001","unstructured":"Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for aids-associated cryptococcal disease. AIDS. 2001;15:2344\u20135.","journal-title":"AIDS"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-010-9375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-010-9375-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-010-9375-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T07:25:20Z","timestamp":1592033120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-010-9375-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,24]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9375"],"URL":"https:\/\/doi.org\/10.1007\/s11046-010-9375-5","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,24]]}}}